Trial Profile
Multicenter, Prospective, Randomised and Comparative Study of AA Therapy and Early Administrating Enzalutamide in Participants With CRPC Previously Treated With CAB Therapy Using Bicalutamide
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Flutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms OCUU-CRPC
- 13 Sep 2021 Results (data cut off: December 31, 2020) presented at the 116th Annual Meeting of the American Urological Association
- 04 Jun 2019 Results of a follow-up observational study presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 16 Feb 2019 Primary endpoint (Percentage of participants whose prostate specific antigen (PSA) decreased 50 percent or more at month 3) has been met as per results presented at the 2019 Genitourinary Cancers Symposium